BusinessGeneral NewsHealthcareIndustryInternational

Alcohol Addiction Market- Adial Pharmaceuticals Inc,Aptinyx Inc,Arbor Pharmaceuticals LLC,AstraZeneca Plc,BioCorRx Inc,Bioprojet SCR,Chronos Therapeutics Ltd

Latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction Market – Pipeline Review, H2 2019, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

Download FREE PDF sample of this Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=2697909

Alcohol Addiction Top Companies Involved in Therapeutics Development
Adial Pharmaceuticals Inc
Aptinyx Inc
Arbor Pharmaceuticals LLC
AstraZeneca Plc
BioCorRx Inc
Bioprojet SCR
Chronos Therapeutics Ltd
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co Ltd
Lohocla Research Corp
Mapreg SAS
Montisera Ltd
Omeros Corp
Opiant Pharmaceuticals Inc
Osmotica Pharmaceutical Corp
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Sosei Heptares
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
Zynerba Pharmaceuticals Inc

Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 5, 21, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the Report:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to buy this Report:
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents in this Report:
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alcohol Addiction – Overview
Alcohol Addiction – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alcohol Addiction – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alcohol Addiction – Companies Involved in Therapeutics Development
Adial Pharmaceuticals Inc
Aptinyx Inc
Arbor Pharmaceuticals LLC
AstraZeneca Plc
BioCorRx Inc
Bioprojet SCR
Chronos Therapeutics Ltd
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co Ltd
Lohocla Research Corp
Mapreg SAS
Montisera Ltd
Omeros Corp
Opiant Pharmaceuticals Inc
Osmotica Pharmaceutical Corp
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Sosei Heptares
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
Zynerba Pharmaceuticals Inc
Alcohol Addiction – Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
18-MC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acamprosate calcium SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BICX-101 SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BICX-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-1.3656B – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-1212 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-15 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCRALDH-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gabapentin enacarbil ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KNX-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAP-4343 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nezavist – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-783 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odelepran – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RC-132 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTI-1395133 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-10406 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Alcohol Use Disorder – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alcohol Addiction – Dormant Projects
Alcohol Addiction – Discontinued Products
Alcohol Addiction – Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: Adial completes final packaging of AD04 for shipment to phase 3 trial clinical sites
Oct 21, 2019: Amygdala Neurosciences awarded $1.35 million NIH grant to conduct long term, phase 3 enabling, toxicology studies
Oct 17, 2019: Adial Pharmaceuticals receives notice of allowance from US Patent and Trademark Office for patent for the treatment of Alcohol Use Disorder in patients identified using a Molecular Genetic Biomarker
Oct 17, 2019: Amygdala Neurosciences announces dosing of the first patient in the NIH funded phase 2 Proof-Of-Concept study of ANS-6637 for the treatment of Alcohol Use Disorder
Oct 07, 2019: BioCorRx announces capital restructuring and provides business update
Oct 01, 2019: Adial files clinical trial application to commence phase 3 trial
Sep 25, 2019: Adial provides update on clinical activities; filing to commence phase 3 trial on track for Q3 2019
Sep 11, 2019: Adial Pharmaceuticals announces successful product retesting of AD04 for phase 3 clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation

and more

Tags

Related Articles

Close